Eli Lilly share price boosted by obesity data for diabetes treatment
The Eli Lilly share has performed better than the broad S&P 500 index so far this year. After positive obesity data was announced for tirzepatide on Tuesday, the share got another boost.
by marketwire, translated by catherine brett
US-based Eli Lilly has had the wind in its sails on the stock market this week.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly squares up to Novo Nordisk on obesity market
For subscribers
Zealand Pharma obesity drug continues to phase II
For subscribers
